컨퍼런스 커버리지 | 학술센터 | 킴스온라인

주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기

최근 해외학술대회의 주요 발표내용을 제공합니다.

컨퍼런스 커버리지

American College of Cardiology 74th Annual Scientific Session & Expo (ACC.25)

29 March - 31 March, 2025, United States

4F-PCC bests frozen plasma as factor replacement for cardiac surgery bleeds

2025-05-29

For physicians requiring coagulation factor replacement to control bleeding after CPB during surgery, 4F-PCC provides superior haemostatic efficacy over frozen plasma, along with some safety advantages, as shown in the FARES-II trial presented at ACC.25
Clopidogrel outshines aspirin for secondary prevention in high-risk PCI patients

2025-05-29

In the long-term maintenance period after percutaneous coronary intervention (PCI), monotherapy with clopidogrel appears to work better than aspirin at preventing major adverse cardiac and cerebrovascular events in Asian patients at high risk of recurrent ischaemic events, as shown in the open-label SMART-CHOICE 3 trial conducted in South Korea.
Dapagliflozin after TAVI improves outcomes in elderly patients with aortic stenosis

2025-05-29

Elderly patients with aortic stenosis who received dapagliflozin after transcatheter aortic-valve implantation (TAVI) had better outcomes than those who did not receive the drug, according to the DapaTAVI* trial presented at ACC.25.
Does CKD reduce tirzepatide benefits on HFpEF patients with obesity?

2025-05-29

Long-term treatment with tirzepatide results in improved renal function in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, regardless of the absence or presence of chronic kidney disease (CKD), according to a post hoc analysis of the SUMMIT trial presented at ACC.25.
Fluid restriction good for chronic HF: Aye or nay?

2025-05-29

Allowing patients with chronic heart failure (HF) to drink as much fluid as they need appears to present no additional risks, including for hospitalization and death, as shown in the FRESH-UP study presented at ACC.25. This finding challenges the current US and EU recommendations to limit daily fluid intake to 1.5 L for this population.
Novel PCSK9 inhibitor for high cholesterol passes phase II trial

2025-05-29

A recent trial presented at ACC.25 has demonstrated the efficacy of AZD0780 in reducing low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia, with a favourable safety and tolerability profile.
Oral semaglutide reduces CV risk in T2D patients

2025-05-29

Once-daily treatment with oral semaglutide, a GLP-1* receptor agonist, significantly reduced the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD), according to the SOUL** trial presented at ACC.25.
Rivaroxaban a game-changer for acute LV thrombus post-MI

2025-05-29

Patients who develop an acute thrombus in the left ventricle (LV) following myocardial infarction (MI) fare equally well when treated with rivaroxaban as they do with warfarin, as shown in the RIVAWAR study.
Semaglutide makes STRIDEs in peripheral artery disease

2025-05-29

Patients with symptomatic peripheral artery disease and type 2 diabetes see notable improvements in their walking capacity and quality of life with once-weekly semaglutide injections in the phase 3b STRIDE study.
Skin pigmentation affects pulse oximeter performance

2025-05-29

Findings from the EquiOx trial presented at ACC.25 underpin the influence of skin pigmentation in pulse oximetry.

1

최근 본 콘텐츠

최근 본 콘텐츠가 없습니다

TOP

주식회사 킴스

주식회사 킴스 | 광고/제휴문의 | 이용약관 | 개인정보처리방침 | 법적 책임의 한계 | 서비스 전체보기

서울특별시 강남구 테헤란로 8길 33 청원빌딩 1층 (주)킴스
개인정보관리책임자 : 최동섭 사업자등록번호 : 214-81-75415 통신판매업신고 : 강남-5166호 대표이사 : 마사키 타카하타
고객센터 : 1544-2930 (10:00~17:00, 주말/공휴일 제외) 팩스 : 02-3019-9380 e-mail : webmaster@kims.co.kr

Copyright © 1987-2025 KIMS Co., Ltd All Rights Reserved

KIMS 페이스북

KIMS 유튜브